Astrazeneca PLC (NYSE:AZN) was downgraded by equities researchers at BidaskClub from a “sell” rating to a “strong sell” rating in a report issued on Friday.

Several other equities analysts also recently issued reports on the stock. Barclays PLC reissued an “overweight” rating on shares of Astrazeneca PLC in a report on Thursday, July 13th. Pareto Securities raised shares of Astrazeneca PLC from a “sell” rating to a “hold” rating in a report on Tuesday, August 1st. Morgan Stanley downgraded shares of Astrazeneca PLC from an “overweight” rating to an “equal weight” rating in a report on Friday, July 28th. Goldman Sachs Group, Inc. (The) reissued a “sell” rating on shares of Astrazeneca PLC in a report on Thursday, July 13th. Finally, Leerink Swann downgraded shares of Astrazeneca PLC from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $36.00 to $31.00 in a report on Thursday, July 27th. Four research analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have assigned a buy rating to the company. Astrazeneca PLC has a consensus rating of “Hold” and an average target price of $33.39.

Shares of Astrazeneca PLC (NYSE AZN) traded down 0.56% during trading on Friday, reaching $30.17. 5,189,646 shares of the company’s stock were exchanged. Astrazeneca PLC has a 52 week low of $25.55 and a 52 week high of $35.60. The stock has a market capitalization of $76.39 billion, a PE ratio of 19.79 and a beta of 0.74. The company’s 50-day moving average is $33.57 and its 200 day moving average is $31.37.

Astrazeneca PLC (NYSE:AZN) last released its quarterly earnings data on Thursday, July 27th. The company reported $0.87 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.46. The firm had revenue of $5.05 billion during the quarter, compared to the consensus estimate of $5.04 billion. Astrazeneca PLC had a net margin of 17.80% and a return on equity of 35.90%. The firm’s revenue was down 9.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.83 earnings per share. On average, analysts forecast that Astrazeneca PLC will post $1.85 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Astrazeneca PLC (NYSE:AZN) Stock Rating Lowered by BidaskClub” was reported by American Banking News and is the property of of American Banking News. If you are reading this report on another website, it was copied illegally and reposted in violation of US and international copyright legislation. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/08/06/astrazeneca-plc-nyseazn-stock-rating-lowered-by-bidaskclub.html.

Large investors have recently modified their holdings of the company. Norges Bank acquired a new stake in shares of Astrazeneca PLC during the fourth quarter valued at approximately $8,217,000. Teachers Advisors LLC boosted its stake in shares of Astrazeneca PLC by 4.0% in the fourth quarter. Teachers Advisors LLC now owns 787,179 shares of the company’s stock valued at $21,506,000 after buying an additional 30,104 shares during the period. Macquarie Group Ltd. boosted its stake in shares of Astrazeneca PLC by 13.1% in the fourth quarter. Macquarie Group Ltd. now owns 485,066 shares of the company’s stock valued at $13,252,000 after buying an additional 56,100 shares during the period. CENTRAL TRUST Co boosted its stake in shares of Astrazeneca PLC by 2.1% in the first quarter. CENTRAL TRUST Co now owns 4,499 shares of the company’s stock valued at $140,000 after buying an additional 91 shares during the period. Finally, Fulton Bank N.A. boosted its stake in shares of Astrazeneca PLC by 44.5% in the first quarter. Fulton Bank N.A. now owns 37,404 shares of the company’s stock valued at $1,164,000 after buying an additional 11,520 shares during the period. Hedge funds and other institutional investors own 14.39% of the company’s stock.

About Astrazeneca PLC

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for Astrazeneca PLC (NYSE:AZN)

Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.